Reported 4 days ago
Hims & Hers Health (HIMS) saw its stock decline after Eli Lilly's weight-loss medications Mounjaro and Zepbound were removed from the FDA's shortage list, indicating that Eli Lilly can now meet market demand. This shift in the market led to concerns for Hims & Hers as they face increased competition.
Source: YAHOO